S. 150 · 118th Congress (2023–2025)
Affordable Prescriptions for Patients Act of 2023
This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.
Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Show official title
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Expired in House
Derived from the legislative history, not an official disposition.
This bill’s path
528 days after it was introduced
This is S. 150’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced17 months
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. John Cornyn (R-TX)
- Cosponsors
8 cosponsors
5 original · 3 later
4 R · 4 D
- Sen. Richard Blumenthal (D-CT)· Original · Jan 30, 2023
- Sen. Ted Cruz (R-TX)· Original · Jan 30, 2023
- Sen. Richard J. Durbin (D-IL)· Original · Jan 30, 2023
- Sen. Chuck Grassley (R-IA)· Original · Jan 30, 2023
- Sen. Amy Klobuchar (D-MN)· Original · Jan 30, 2023
- Sen. Mike Braun (R-IN)· Later · May 2, 2023
- Sen. Peter Welch (D-VT)· Later · May 2, 2023
- Sen. Lisa Murkowski (R-AK)· Later · Apr 9, 2024
- Policy area
- Health
- Subjects
- Administrative remedies
- Civil actions and liability
- Competition and antitrust
- Consumer affairs
- Drug safety, medical device, and laboratory regulation
- Federal Trade Commission (FTC)
- Health care costs and insurance
- Inflation and prices
4 more
- Intellectual property
- Judicial review and appeals
- Manufacturing
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
1 amendment
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
▸ 3 committee actions · Jan 30, 2023 – Mar 1, 2023
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Sources
- Congress.gov action
- Senate
S.Amdt. 2399, adopted
Major substitute
Offered by Sen. John Cornyn (R-TX)
Amendment SA 2399 agreed to in Senate by Unanimous Consent.
In the nature of a substitute.
Document: Engrossed in Senate
Sources
- Congress.gov amendmentS.Amdt. 2399
- Latest
Passed Senate
Congressional Record S4537–S4538
Passed Senate with an amendment by Unanimous Consent.
The Senate passed the amended bill.
Document: Engrossed in Senate
Sources
- Congress.gov action
- Senate
Expired
Passed Senate → Held at the desk → No further action before the 118th Congress ended.
Committees
Feb 9, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Affordable Prescriptions for Patients Act of 2023
Display title, Short title · Engrossed in Senate, Introduced in Senate, Reported to Senate
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Official title · Introduced in Senate